Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting

-Multiple SNS-723 CAR constructs demonstrated significant expression of ASPH-specific CARs on T-cells, dose-dependent cell killing, and cytokine responses

-Dose-dependent and durable ASPH-specific immune responses observed in patients dosed with SNS-301, consistent with earlier findings

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics,